Onyx Pharmaceuticals »

  • Business » Amgen’s cancer deal
    August 27, 2013, 08:44 GMT

    Amgen (NASDAQ:AMGN) made headlines on Monday morning when it was announced the long awaited deal with Onyx Pharmaceuticals finally closed. An approaching patent cliff has pushed the company to look for large deals within the pharma space. Onyx has agreed to sell for roughly $10.4 billion in cash, making the deal one of the largest